MoonLake ImmunotherapeuticsNASDAQ:MLTX
- LAST PRICE42.9350
- TODAY'S CHANGE (%)0.6850 (1.6213%)
- Bid / Lots42.7400/ 1
- Ask / Lots42.9500/ 4
- Open / Previous Close42.3700 / 42.2500
- Day Range
- 52 Week Range
- Volume49,058
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MLTX |
|---|---|---|
| 09:32 ET | 544 | 42.37 |
| 09:38 ET | 100 | 42.727 |
| 09:39 ET | 8200 | 42.415 |
| 09:43 ET | 800 | 42.7 |
| 09:45 ET | 100 | 42.85 |
| 09:48 ET | 100 | 42.88 |
| 09:50 ET | 100 | 42.63 |
| 09:56 ET | 100 | 42.82 |
| 09:57 ET | 100 | 42.815 |
| 09:59 ET | 100 | 42.979 |
| 10:01 ET | 100 | 42.89 |
| 10:06 ET | 200 | 42.84 |
| 10:08 ET | 1050 | 42.8539 |
| 10:14 ET | 100 | 42.71 |
| 10:15 ET | 100 | 42.755 |
| 10:17 ET | 400 | 42.68 |
| 10:24 ET | 300 | 42.625 |
| 10:28 ET | 100 | 42.65 |
| 10:30 ET | 1100 | 42.9 |
| 10:32 ET | 1612 | 42.74 |
| 10:33 ET | 1291 | 42.5 |
| 10:37 ET | 300 | 42.545 |
| 10:42 ET | 1210 | 42.49 |
| 10:44 ET | 100 | 42.425 |
| 10:46 ET | 350 | 42.5 |
| 10:48 ET | 100 | 42.525 |
| 10:50 ET | 200 | 42.515 |
| 10:51 ET | 204 | 42.485 |
| 10:57 ET | 500 | 42.6 |
| 11:02 ET | 200 | 42.48 |
| 11:04 ET | 795 | 42.485 |
| 11:06 ET | 200 | 42.385 |
| 11:08 ET | 300 | 42.37 |
| 11:15 ET | 400 | 42.27 |
| 11:20 ET | 200 | 42.26 |
| 11:22 ET | 200 | 42.2 |
| 11:27 ET | 890 | 42.17 |
| 11:31 ET | 100 | 42.18 |
| 11:40 ET | 300 | 42.255 |
| 11:44 ET | 100 | 42.35 |
| 11:47 ET | 100 | 42.3 |
| 11:49 ET | 250 | 42.36 |
| 11:54 ET | 300 | 42.305 |
| 11:58 ET | 400 | 42.34 |
| 12:00 ET | 100 | 42.4 |
| 12:02 ET | 200 | 42.37 |
| 12:03 ET | 100 | 42.365 |
| 12:05 ET | 100 | 42.37 |
| 12:07 ET | 400 | 42.37 |
| 12:09 ET | 100 | 42.365 |
| 12:12 ET | 1500 | 42.44 |
| 12:14 ET | 500 | 42.44 |
| 12:18 ET | 239 | 42.485 |
| 12:20 ET | 890 | 42.485 |
| 12:23 ET | 460 | 42.475 |
| 12:27 ET | 2300 | 42.425 |
| 12:30 ET | 100 | 42.415 |
| 12:32 ET | 789 | 42.535 |
| 12:41 ET | 200 | 42.525 |
| 12:52 ET | 100 | 42.49 |
| 12:57 ET | 100 | 42.565 |
| 12:59 ET | 900 | 42.935 |
Apr 23, 2024
DJ MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co., from 6:36AM ET on Tuesday Apr 23, 2024 by Dow Jones
6:36AM ET on Tuesday Apr 23, 2024 by Dow Jones
Apr 11, 2024
DJ MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co., from 7:37AM ET on Thursday Apr 11, 2024 by Dow Jones
7:37AM ET on Thursday Apr 11, 2024 by Dow Jones
Apr 10, 2024
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions, from 7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
7:00AM ET on Wednesday Apr 10, 2024 by Dow JonesMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions, from 7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 9, 2024
DJ MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham, from 6:08AM ET on Tuesday Apr 09, 2024 by Dow Jones
6:08AM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MoonLake Immunotherapeutics | 2.7B | -56.3x | --- |
Apogee Therapeutics Inc | 2.6B | -27.1x | --- |
Summit Therapeutics Inc | 2.5B | -2.5x | --- |
CG Oncology Inc | 2.4B | -37.8x | --- |
Janux Therapeutics Inc | 2.4B | -35.9x | --- |
Merus NV | 2.6B | -15.2x | --- |
Company Information
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Contact Information
- Headquarters
- Dorfstrasse 29ZUG, ZUG, Switzerland 6300
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Simon Sturge
- Chief Executive Officer, Director
- Jorge Santos Da Silva
- Chief Financial Officer
- Matthias Bodenstedt
- Chief Scientific Officer
- Kristian Reich
- Independent Director
- Kara Lassen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 63.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $-0.76 |
Book Value | $8.20 |
P/E Ratio | -56.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
